<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Acetazolamide</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00819</strong>&#160; (APRD00119, EXPT00604)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00819/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00819/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00819.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00819.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00819.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00819.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00819.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00819">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Acetazolamid</td><td>German </td><td>INN</td></tr><tr><td>Acetazolamida </td><td>Spanish</td><td>INN</td></tr><tr><td>Ac&#233;tazolamide</td><td>French</td><td>INN</td></tr><tr><td>Acetazolamidum</td><td>Latin </td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Acetazolamide Sodium</strong>
          <div class="cas">1424-27-7</div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000539/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000539/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: </li>
              <li>Monoisotopic Mass: </li>
              <li>Average Mass: </li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000539">DBSALT000539</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Acemit</td><td>Medphano</td></tr><tr><td>Acemox</td><td>Acme</td></tr><tr><td>Acetak</td><td>Akorn</td></tr><tr><td>Acetamide</td><td>Micro Vision</td></tr><tr><td>Acetazolamax</td><td>Pfoshen</td></tr><tr><td>Avva</td><td>Intas</td></tr><tr><td>Azm</td><td>Ethical</td></tr><tr><td>Azol</td><td>New Chemical</td></tr><tr><td>Azomid</td><td>Adcock Ingram Pharmaceuticals</td></tr><tr><td>Carbinib</td><td>Edol</td></tr><tr><td>D&#233;filtran</td><td>CSP</td></tr><tr><td>Defiltran</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Diabo</td><td>Raymos</td></tr><tr><td>Diacarb</td><td>Polpharma</td></tr><tr><td>Diamox</td><td>Sanofi Aventis</td></tr><tr><td>Diamox Depot</td><td>Goldshield</td></tr><tr><td>Diamox Sequels</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Diazomid</td><td>Sanofi-Aventis</td></tr><tr><td>Diluran</td><td>Zentiva</td></tr><tr><td>Diuramid</td><td>Polpharma</td></tr><tr><td>Edemox</td><td>Chiesi</td></tr><tr><td>Glaumox</td><td>Phebra</td></tr><tr><td>Glaupax</td><td>Omnivision</td></tr><tr><td>Glupax</td><td>Phebra</td></tr><tr><td>Huma-Zolamide</td><td>Teva</td></tr><tr><td>Iopar-SR</td><td>FDC</td></tr><tr><td>Medene</td><td>Pharmaland</td></tr><tr><td>Oculten</td><td>Acromax</td></tr><tr><td>&#214;demin</td><td>Santen</td></tr><tr><td>Uramox</td><td>Taro</td></tr><tr><td>Zolmide</td><td>Vista Pharma</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/diuretics">Diuretics</a></li>
<li><a href="/mesh/anticonvulsants">Anticonvulsants</a></li>
<li><a href="/mesh/carbonic-anhydrase-inhibitors">Carbonic Anhydrase Inhibitors</a></li></ul></td></tr><tr><th>CAS number</th><td>59-66-5</td></tr><tr><th>Weight</th><td>Average: 222.245<br>Monoisotopic: 221.988131458</td></tr><tr><th>Chemical Formula</th><td>C<sub>4</sub>H<sub>6</sub>N<sub>4</sub>O<sub>3</sub>S<sub>2</sub></td></tr><tr><th>InChI Key</th><td>BZKPWHYZMXOIDC-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C4H6N4O3S2/c1-2(9)6-3-7-8-4(12-3)13(5,10)11/h1H3,(H2,5,10,11)(H,6,7,9)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)acetamide</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC(=O)NC1=NN=C(S1)S(N)(=O)=O</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB00819.gif?1265922772">show</a>(8.82 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Azoles</td></tr><tr><th>Subclass</th><td>Thiadiazoles</td></tr><tr><th>Direct parent</th><td>Aminothiadiazoles</td></tr><tr><th>Alternative parents</th><td>Sulfonyls; Sulfonamides; Secondary Carboxylic Acid Amides; Polyamines; Enolates; Carboxylic Acids</td></tr><tr><th>Substituents</th><td>sulfonic acid derivative; sulfonyl; sulfonamide; secondary carboxylic acid amide; carboxamide group; carboxylic acid derivative; polyamine; enolate; carboxylic acid; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the aminothiadiazoles. These are thiadiazoles with an amino group attached to the thiadiazole ring.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies; chronic simple (open-angle) glaucoma</td></tr><tr><th>Pharmacodynamics</th><td>Acetazolamide is a potent carbonic anhydrase inhibitor, effective in the control of fluid secretion, in the treatment of certain convulsive disorders and in the promotion of diuresis in instances of abnormal fluid retention. Acetazolamide is not a mercurial diuretic. Rather, it is a nonbacteriostatic sulfonamide possessing a chemical structure and pharmacological activity distinctly different from the bacteriostatic sulfonamides.</td></tr><tr><th>Mechanism of action</th><td>The anticonvulsant activity of Acetazolamide may depend on a direct inhibition of carbonic anhydrase in the CNS, which decreases carbon dioxide tension in the pulmonary alveoli, thus increasing arterial oxygen tension. The diuretic effect depends on the inhibition of carbonic anhydrase, causing a reduction in the availability of hydrogen ions for active transport in the renal tubule lumen. This leads to alkaline urine and an increase in the excretion of bicarbonate, sodium, potassium, and water.</td></tr><tr><th>Absorption</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>98%</td></tr><tr><th>Metabolism</th><td class="data-table-container"></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>3 to 9 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9156</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9382</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.7761</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.8369</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9267</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9507</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9365</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7316</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.7817</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9259</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9071</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9625</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9026</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9037</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8798</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.8445
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.802
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9301
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          1.8939 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9926
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9449
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Zydus pharmaceuticals usa inc</li>
<li>Duramed pharmaceuticals inc sub barr laboratories inc</li>
<li>Alra laboratories inc</li>
<li>Ascot hosp pharmaceuticals inc div travenol laboratories inc</li>
<li>Lannett co inc</li>
<li>Mutual pharmaceutical co inc</li>
<li>Taro pharmaceutical industries ltd</li>
<li>Vangard laboratories inc div midway medical co</li>
<li>Watson laboratories inc</li>
<li>Bedford laboratories div ben venue laboratories inc</li>
<li>Hospira inc</li>
<li>X gen pharmaceuticals inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>American Cyanamid Co.</li>
<li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li>Barr Pharmaceuticals</li>
<li><a href="http://www.bedfordlabs.com">Bedford Labs</a></li>
<li><a href="http://www.benvenue.com">Ben Venue Laboratories Inc.</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li>Direct Dispensing Inc.</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dsm.com">DSM Corp.</a></li>
<li><a href="http://www.duramed.ca">Duramed</a></li>
<li><a href="http://www.emcure.co.in">Emcure Pharmaceuticals Ltd.</a></li>
<li>Heartland Repack Services LLC</li>
<li>Innovative Manufacturing and Distribution Services Inc.</li>
<li>Kaiser Foundation Hospital</li>
<li><a href="http://www.lannett.com">Lannett Co. Inc.</a></li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li>Mutual Pharmaceutical Co.</li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.prescript.net">Prescript Pharmaceuticals</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://www.tarousa.com">Taro Pharmaceuticals USA</a></li>
<li><a href="http://www.urlpharma.com">United Research Laboratories Inc.</a></li>
<li><a href="http://www.watson.com">Watson Pharmaceuticals</a></li>
<li><a href="http://www.x-gen.us">X-Gen Pharmaceuticals</a></li>
<li><a href="http://www.zydususa.com">Zydus Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00945">Acetylsalicylic acid</a></td><td>Acetylsalicylic acid at high dose increases the effect of the carbonic anhydrase inhibitor, acetazolamide.</td></tr><tr><td><a href="/drugs/DB01294">Bismuth Subsalicylate</a></td><td>The salicylate, bismuth subsalicylate, at high dose increases the effect of the carbonic anhydrase inhibitor, acetazolamide.</td></tr><tr><td><a href="/drugs/DB01194">Brinzolamide</a></td><td>As both brinzolamide and acetazolamide are carbonic anhydrase inhibitors, there is an increased risk of adverse effects.The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Avoid concurrent use of different carbonic anhydrase inhibitors when possible.</td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>Acetazolamide may increase the effect and toxicity of cyclosporine.</td></tr><tr><td><a href="/drugs/DB01043">Memantine</a></td><td>Possible increased levels of memantine</td></tr><tr><td><a href="/drugs/DB00684">Tobramycin</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB00273">Topiramate</a></td><td>Additive renal carbonic anhydrase inhibition may occur increasing the risk of crystaluria and renal calculi. Increased risk of nephrolithiasis. Consider altnerate therapy. </td></tr><tr><td><a href="/drugs/DB00374">Treprostinil</a></td><td>Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. </td></tr><tr><td><a href="/drugs/DB00427">Triprolidine</a></td><td>The CNS depressants, Triprolidine and Acetazolamide, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Drink plenty of liquids.</li>
<li>Take with food; at least 6 hours before bedtime.</li></ul></td></tr></tbody></table>